Di Renzo M, Pasqui A L, Bruni F, Saletti M, Bova G, Chiarion C, Girardello R, Ferrì P, Auteri A
Department of Clinical Immunology, University of Siena, Italy.
Immunopharmacol Immunotoxicol. 1997 Feb;19(1):37-51. doi: 10.3109/08923979709038532.
There are several reports concerning an impairment of cellular immune response in patients affected by malignant disease. The aim of this study was to evaluate the in vitro effect of Pidotimod, a synthetic biological response modifier, on some immune functions in 14 cancer patients. In particular, we showed that these subjects had a significantly reduced peripheral blood mononuclear cell (PBMC) proliferation both in response to PHA and to Con A in comparison with a group of healthy subjects. Besides, they showed a significantly reduced PBMC IL2 production, which was evaluated both through an ELISA method and a biological assay. The in vitro addition of increasing concentrations of Pidotimod (10, 25 and 50 ug/ml) was able to enhance PBMC proliferation and IL2 production significantly. However, in spite of the addition of Pidotimod, both immune functions in our neoplastic patients did not reach normal values.
有几篇关于恶性疾病患者细胞免疫反应受损的报道。本研究的目的是评估合成生物反应调节剂匹多莫德对14例癌症患者某些免疫功能的体外作用。特别是，我们发现与一组健康受试者相比，这些受试者对PHA和Con A的外周血单个核细胞（PBMC）增殖均显著降低。此外，他们的PBMC IL2产生显著减少，这通过ELISA方法和生物学测定进行评估。体外添加浓度递增的匹多莫德（10、25和50μg/ml）能够显著增强PBMC增殖和IL2产生。然而，尽管添加了匹多莫德，我们肿瘤患者的两种免疫功能均未达到正常值。
